Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251 · not yet recruiting · No results posted in this snapshot
All research
COMPOUND RESEARCH
CagriSema
Follow the papers. Understand the context.
10 papers · 4 trial recordsChecked 18 Sept 2026
CagriSema is a combination of cagrilintide and semaglutide. Evidence for either ingredient alone is not automatically evidence for the combination.
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869 · completed · No results posted in this snapshot
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
NCT07184086 · active not recruiting · No results posted in this snapshot
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
NCT06323161 · completed · No results posted in this snapshot
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacology · Abstract available
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Diabetes, obesity & metabolism · Abstract available
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
Annals of medicine and surgery (2012) · Abstract available
Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.
Journal of diabetes science and technology · Abstract available
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England) · Abstract available
Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
The lancet. Diabetes & endocrinology · Citation only
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinology · Abstract available
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
The lancet. Diabetes & endocrinology · Abstract available
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
Journal of diabetes and metabolic disorders · Abstract available
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
The lancet. Diabetes & endocrinology · Abstract available
Publications match compound names in their titles. Trial matches use intervention names. An association with a compound is not a finding about its effectiveness. How we select records.